Galectin NASH treatment meets primary endpoint in Phase 1

• At The Liver Meeting in Boston, Galectin Therapeutics (NASDAQ:GALT) presented Phase 1 results for GR-MD-02, its investigational galectin inhibitor for the treatment of nonalcoholic steatohepatitis (NASH). Data from the administration of 2,4 and 8 mg/kg lean body weight of GR-MD-02 intravenously for four doses over six weeks was safe and well tolerated. This was the primary endpoint.
• The company met recently with the FDA to discuss the initiation of a Phase 2 study.
• Shares are up 13% premarket on light volume.